TGFBR2 and Miyoshi myopathy: Promoter hypermethylation of CDKN2A, which is a marker for overall epigenetic changes, and TGFBR2 have been shown to correlate with poor prognosis in MM patients, although the prognostic value of CDKN2A hypermethylation remains debatable [6].